New Patents Add Value to Know Labs’ Bio-RFID Tech

Know Labs Inc. has been granted two new foundational patents that add significant value to its IP portfolio and proprietary Bio-RFID technology. The two patents protect the ability to create and utilize any database built with data captured through non-invasive sensors. This widens the technological gap between Know Labs and others pursuing non-invasive diagnostics, while opening up a much broader range of protection for non-invasive analyte data collection and management, beyond human health.

Issued by the U.S. Patent and Trademark Office, the new patents are titled “Analyte Database Established Using Analyte Data from a Non-Invasive Analyte Sensor” and “Analyte Database Established Using Analyte Data from Non-Invasive Analyte Sensors.” Both patents refer to the process of deriving an analyte database from one or multiple subjects and from one or multiple non-invasive sensors across a broad range of analytes, meaning the process of non-invasively capturing, organizing, and analyzing analytes in the form of a database.

“In simple terms, this means Know Labs now controls any analyte database built with data captured through non-invasive sensors,” said Ron Erickson, Know Labs board chairman. “Our company already has foundational patents covering more than 100 different analytes that are important to a diverse set of industries. By combining these analyte patents with the newly issued database patents, we are securing new applications for Bio-RFID, which builds tremendous value for Know Labs shareholders. As we’ve been saying for a long time, executing a disciplined intellectual property strategy is key for our success, so we dedicate a lot of time and energy to it. We expect to be granted more patents soon and, in the meantime, remain focused on the internal clinical trial of our glucose monitoring device, which leverages the analyte database IP.”

Know Labs believes it will be the first company to bring a U.S. Food and Drug Administration (FDA)-cleared non-invasive glucose monitoring device to market. The company is currently conducting a 200-person internal clinical trial of Bio-RFID, which will help Know Labs refine its algorithm and demonstrate Bio-RFID’s accuracy in a large population while collecting additional data for a pre-submission meeting with the FDA.

“We have successfully patented the process to accurately and non-invasively collect data, build a database from this data, and process it with AI algorithms,” said Phil Bosua, Know Labs CEO. “All of these parts are critical to launching a commercial diagnostic platform and now we control them. This further demonstrates how Know Labs and our technology have the potential to disrupt the medical diagnostic industry and potentially many others.”

These new patents bring Know Labs’ patent portfolio to 78 issued and pending. 

Know Labs is a public company whose technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The company refers to its technology as Bio-RFID. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of its Bio-RFID technology will be in a product marketed as a non-invasive glucose monitor. It will provide the user with real-time information on blood glucose levels. This product will require FDA approval prior to its introduction to the market.